- Home
- INCY vs RGA Comparison
INCY vs RGA Comparison
Compare INCY & RGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- RGA
- Stock Information
- Founded
- INCY 1991
- RGA 1973
- Country
- INCY United States
- RGA United States
- Employees
- INCY N/A
- RGA N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- RGA Life Insurance
- Sector
- INCY Health Care
- RGA Finance
- Exchange
- INCY Nasdaq
- RGA Nasdaq
- Market Cap
- INCY 17.0B
- RGA 12.4B
- IPO Year
- INCY 1993
- RGA 1993
- Fundamental
- Price
- INCY $105.22
- RGA $189.59
- Analyst Decision
- INCY Buy
- RGA Buy
- Analyst Count
- INCY 19
- RGA 10
- Target Price
- INCY $89.19
- RGA $239.89
- AVG Volume (30 Days)
- INCY 2.8M
- RGA 442.4K
- Earning Date
- INCY 10-28-2025
- RGA 10-30-2025
- Dividend Yield
- INCY N/A
- RGA 1.96%
- EPS Growth
- INCY 3878.02
- RGA 18.96
- EPS
- INCY 5.90
- RGA 12.98
- Revenue
- INCY $4,813,105,000.00
- RGA $22,304,000,000.00
- Revenue This Year
- INCY $19.33
- RGA $7.57
- Revenue Next Year
- INCY $10.47
- RGA $10.61
- P/E Ratio
- INCY $17.95
- RGA $14.61
- Revenue Growth
- INCY 18.09
- RGA 1.97
- 52 Week Low
- INCY $53.56
- RGA $159.25
- 52 Week High
- INCY $106.47
- RGA $233.81
- Technical
- Relative Strength Index (RSI)
- INCY 79.03
- RGA 50.57
- Support Level
- INCY $91.16
- RGA $178.21
- Resistance Level
- INCY $106.47
- RGA $192.21
- Average True Range (ATR)
- INCY 4.10
- RGA 4.59
- MACD
- INCY 1.59
- RGA 0.18
- Stochastic Oscillator
- INCY 94.41
- RGA 78.70
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About RGA Reinsurance Group of America Incorporated
Reinsurance Group of America Inc is an insurance holding company with operations in the United States, Latin America, Canada, Europe, Africa, Asia, and Australia. The core products and services include life reinsurance, living benefits reinsurance, group reinsurance, health reinsurance, financial solutions, facultative underwriting, and product development. The company's operations are divided into traditional and financial solution businesses.